Trial · NCT04589845
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845, Phase 2, Active not recruiting, Hoffmann-La Roche
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study. Trials, record NCT04589845. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04589845
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT number
- NCT04589845
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 920 participants, estimated
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Solid Tumors
- Interventions
- Entrectinib, Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib
- First posted
- 2020-10-19
- Last updated
- 2026-09-04
- Other registries' IDs
- eudract:2020-001847-16
Source ClinicalTrials.gov
Registered outcomes41
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) | Approximately up to 12 years | Confirmed objective response indicates ≥4 weeks after initial documentation of response. |
| Secondary | All Cohorts: IRC-assessed Duration of Response (DOR) per RECIST v1.1 | Approximately up to 12 years | |
| Secondary | All Cohorts: IRC-assessed Clinical Benefit Rate (CBR) per RECIST v1.1 | Approximately up to 12 years | |
| Secondary | All Cohorts: IRC-assessed Progression-free Survival (PFS) per RECIST v1.1 | Approximately up to 12 years | |
| Secondary | All Cohorts: Investigator (INV)-assessed ORR per RECIST v1.1 | Approximately up to 12 years | |
| Secondary | All Cohorts: INV-assessed DOR per RECIST v1.1 | Approximately up to 12 years | |
| Secondary | All Cohorts: INV-assessed CBR per RECIST v1.1 | Approximately up to 12 years | |
| Secondary | All Cohorts: INV-assessed PFS per RECIST v1.1 | Approximately up to 12 years | |
| Secondary | All Cohorts: IRC- and INV-assessed Time to Central Nervous System (CNS) Progression per RECIST v1.1 | Approximately up to 12 years | |
| Secondary | All Cohorts: Overall Survival (OS) | Approximately up to 12 years |
1 to 10 of 41Source ClinicalTrials.gov
See all 41 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04589845
GET https://conductscience.org/api/trials/v1/NCT04589845/registered?page=2